Enovis CORP (ENOV) research
Enovis CORP- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $17.77
- As of
Enovis CORP (ENOV): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-01.
As of . Source: SEC EDGAR filings for ENOV. Method and limitations.
Share the ENOV intelligence card
See the full ENOV dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ENOV on one page. Preview it with sample data, then open it live with a free account.
Preview the ENOV dossierActive signals for ENOV
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 71% of ENOV (2026Q2)
- highINSTITUTIONAL_SURGE
Bridgewater Associates, LP added +50% to ENOV (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +51% to ENOV (2026Q1)
- mediumNEW_POSITION
Bridgewater Associates, LP new position in ENOV
- mediumEARNINGS_BEAT
Q1-2026: Beat consensus by 6.8% - EPS $0.89 vs $0.833 estimate
FREE, NO ACCOUNT
Every signal on ENOV, as it fires
You are seeing 5 of 9 signals recorded on ENOV since 2026-05-29.
The five above landed across 3 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ENOV (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 194014502 · 2026Q2 | $16.6M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 194014502 · 2026Q2 | $1.7M | 0.00% | , |
| Bridgewater Associates, LPCUSIP 194014502 · 2026Q2 | $1.6M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ENOV
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ENOV against its peers
ENOV's operating margin of -50.0% ranks in the 26th percentile of 20 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-28 and 2025-12-31.
| Metric | ENOV | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 2.2B USD | 218M USD | 93 | 20 |
| Gross margin | 59.8% | 69.1% | 39 | 18 |
| Operating margin | -50.0% | -16.5% | 26 | 20 |
| Net margin | -52.7% | -14.0% | 21 | 20 |
| Return on equity | -79.5% | -16.3% | 17 | 20 |
| P / E | n/a | 34.4x | n/a | 5 |
Peers (20): BBNX, AORT, AVNS, CBLL, IART, SIBN, INMD, QDEL, SSII, KIDS, ESTA, DCTH, MASS, SENS, TCMD, UFPT, NPCE, BFLY, AXGN, OFIX. Left out: LMRI (no annual filing), NHNKF (no annual filing), OSSUY (no annual filing), BWAY (period gap), ALMR (no annual filing). Fiscal periods ending between 2025-12-28 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ENOV: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ENOV signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ENOVand get the insider, 13F, options, and confluence read in one view.